Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Mallinckrodt
Baxter
McKinsey
Merck

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fotemustine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Fotemustine: Patents, clinical trial progress, indications

Fotemustine is an investigational drug.

There have been 16 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.

There is one US patent protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for Fotemustine
TitleSponsorPhase
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaMingzhi ZhangPhase 4
A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTGenenta SciencePhase 1/Phase 2
MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma PatientsAzienda Sanitaria di FirenzePhase 2/Phase 3

See all Fotemustine clinical trials

Clinical Trial Summary for Fotemustine

Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine

See all Fotemustine clinical trials

US Patents for Fotemustine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fotemustine   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Fotemustine   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Fotemustine   Start Trial Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Start Trial
Fotemustine   Start Trial Bispecific antigen-binding constructs targeting HER2 Zymeworks Inc. (Vancouver, CA)   Start Trial
Fotemustine   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Fotemustine   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fotemustine

Drugname Country Document Number Estimated Expiration Related US Patent
Fotemustine World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Fotemustine Australia 2015231053 2034-03-21   Start Trial
Fotemustine Brazil 112016021620 2034-03-21   Start Trial
Fotemustine Canada 2943339 2034-03-21   Start Trial
Fotemustine China 106231900 2034-03-21   Start Trial
Fotemustine Eurasian Patent Organization 201691896 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
AstraZeneca
Mallinckrodt
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.